The Gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin)

References

• . Jones PH, Davidson MH, Stein EA, ; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 92(2):152–160
   PubMed Web of Science ®Google Scholar
• . Kjekshus J, Apetrei E, Barrios V, ; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357(22):2248–2261
   PubMed Web of Science ®Google Scholar
• . GISSI-HF Investigators; Tavazzi L, Maggioni AP, Marchioli R, . Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–1239
   PubMedGoogle Scholar
• . Ridker PM, Danielson E, Fonseca FA, ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . Glynn RJ, Danielson E, Fonseca FA, . A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. [published online ahead of print March 29, 2009]. N Engl J Med.
   Google Scholar
• . Goldstein LB. JUPITER and the world of stroke medicine. Lancet Neurol. 2009;8(2):129–131
   PubMedGoogle Scholar
• . Ridker PM, Danielson E, Fonseca FA, ; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009; 373(9670):1175–1182
   PubMed Web of Science ®Google Scholar
• . Belluck P. Cholesterol-fighting drugs show wider benefit. New York Times. November 10, 2008:A1
   Google Scholar
• . Downs JR, Clearfield M, Tyroler HA, . Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87(9):1074–1079
   PubMed Web of Science ®Google Scholar
• . Shepherd J, Cobbe SM, Ford I, . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–1307
   PubMed Web of Science ®Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, ; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685–696
   PubMed Web of Science ®Google Scholar
• . Sever PS, Dahlöf B, Poulter NR, ; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364):1149–1158
   PubMed Web of Science ®Google Scholar
• . O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11):2142–2146
   PubMed Web of Science ®Google Scholar
• . Cordain L, Eaton S, Brand Miller J, Mann N, Hill K. The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic. Eur J Clin Nutr. 2002;56( suppl 1):S42–S52
   PubMed Web of Science ®Google Scholar
• . Baschetti R. Evolution, cholesterol, and low-fat diets. Circulation. 1997;99(1):164–167
   Google Scholar
• . Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24(5):1359–1362
   PubMed Web of Science ®Google Scholar
• . Sattar N, Gaw A, Scherbakova O, . Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414–419
   PubMed Web of Science ®Google Scholar
• . Lavie CJ, Milani RV. Cardiac rehabilitation and exercise training programs in metabolic syndrome and diabetes. J Cardiopulm Rehabil. 2005;25(2):59–66
   PubMedGoogle Scholar
• . Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391–397
   PubMed Web of Science ®Google Scholar
• . Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92–97
   PubMed Web of Science ®Google Scholar
• . Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety? Mayo Clin Proc. 2007;82(5):539–542
   PubMed Web of Science ®Google Scholar
• . O'Keefe JH, Bybee KA, Lavie CJ. Intensive lipid intervention in the post-ENHANCE era. Mayo Clin Proc. 2008;83(8):867–869
   PubMed Web of Science ®Google Scholar
• . Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem. 2009;55(2):219–228
   PubMedGoogle Scholar
• . O'Keefe JH Jr, Cordain L, Jones PG, Abuissa H. Coronary artery disease prognosis and C-reactive protein levels improve in proportion to percent lowering of low-density lipoprotein. Am J Cardiol. 2006;98(1):135–139
   PubMedGoogle Scholar
• . Nissen SE, Tuzcu EM, Schoenhagen P, ; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352(1):29–38
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Cannon CP, Morrow D, ; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352(1):20–28
   PubMed Web of Science ®Google Scholar
• . Mitka M. Researchers worry about myopathy risk for patients taking high-dose simvastatin. JAMA. 2009;301(3):261–262
   PubMedGoogle Scholar
• . Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc. 2008;83(12):1316–1325
   PubMed Web of Science ®Google Scholar
• . Pedersen TR, Faergeman O, Kastelein JJ, . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445
   PubMed Web of Science ®Google Scholar
• . de Lemos JA, Blazing MA, Wiviott SD, ; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292(11):1307–1316
   PubMed Web of Science ®Google Scholar
• . Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49(17):1753–1762
   PubMed Web of Science ®Google Scholar
• . Musunuru K, Kral BG, Blumenthal RS, . The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008;5(10):621–635
   PubMedGoogle Scholar